New gene defect discovery helps to unlock the mystery of severe infectious mononucleosis
A new hereditary disease was found in Finns, which manifests as severe infectious mononucleosis. The genetic defect can lead to the treatment of many different diseases.
![Mikko Seppänen](/data/images/public/23980819/70129471/6d6cc4d1-d861-4835-ae53-4aa018d27ddd-w_720.jpg)
Almost all Finns suffer from symptomatic or asymptomatic “kissing disease”, or infectious mononucleosis (IM), at a young age, which is an infection caused by the Epstein-Barr virus (EBV). A small part of the patients requires hospital care.
About 95 per cent of Finns are infected with the Epstein-Barr virus, which spreads through saliva. Most are exposed to the virus as a child, either without symptoms or with infectious mononucleosis as the only symptom. The symptoms of severe infectious mononucleosis are usually fever and severely swollen lymph nodes and spleen. Symptoms requiring hospital care include severe inflammatory symptoms, severe lymphatic tissue hyperplasia (overgrowth), decline in general condition and rupture of the spleen.
New Finnish gene defect discovered
A new gene defect was discovered in the Finnish population, which, if inherited from both parents, may cause severe infectious mononucleosis but also help you cope with it.
"This is a new hereditary disease in Finland, and around 300 Finns have it. One of its manifestations is severe infectious mononucleosis, which eventually heals on its own", says Chief Physician Mikko Seppänen from HUS Children and Adolescents and the University of Helsinki.
The study published in the prestigious science journal Nature was carried out in international cooperation, which also included one of the principal researchers of the FinnGen project, Mark Daly from the University of Helsinki.
Hope for new treatments for serious diseases
Some people with severe infectious mononucleosis are later diagnosed with other diseases associated with the Epstein-Barr virus, such as lymphatic tissue hyperplasia, which may lead to lymph node cancers or severe lymph node inflammation.
Everyone infected with the EBV carry the virus for the rest of their life. The study revealed that the gene defect prevented the gene from functioning, making it unable to communicate in its communication pathway. This led to a sudden inflammation with more symptoms than usual. At the same time, the gene defect surprisingly appeared to protect against uncontrolled general inflammation and life-threatening lymphatic tissue growth leading to tumor diseases. These can appear quickly in many hereditary immune deficiencies, or even decades later in drug-induced immune deficiencies. In other words, a functional gene was required for the uncontrolled overgrowth of lymphatic tissue.
"In the future, we are interested in whether the progression of lymphatic hyperplasia could be prevented by a treatment that silences the communication pathway found. If it works, we might be able to stop the progression of many of the most difficult blood cancers and lymph node tumors," Mikko Seppänen says.
The study monitored the patients for only a few years, so preparations for a new study have already begun. The aim is to find out whether Finnish biobanks and the children treated for infectious mononucleosis at the New Children's Hospital have this genetic defect.
"Biobank research can quickly determine whether these children should be prepared for the risk of an immune disease later in life. At the same time, we will find out the whole spectrum of the disease," says Seppänen.
Finnish biobanks and FinnGen project played a key role in the discovery
The study was launched at the Institute Imagine and Université Paris Cité, which specialize in genetic diseases in France, where three French children with severe infectious mononucleosis were examined for rare genetic defects. Severe mononucleosis infections are very rare in Central and Southern Europe.
Through HUS, the French contacted the FinnGen project, which covers the whole of Finland and contains genome and health register data for more than 540,000 Finns. An analysis carried out by FinnGen confirmed that the gene defect may cause severe infectious mononucleosis.
Kymenlaakso, Helsinki region and Savo have the highest number of carriers of the Finnish gene defect. The gene defect is approximately 50 times more common in Finns than in other populations.
Link to research article:
Role of IL-27 in Epstein–Barr virus infection revealed by IL-27RA deficiency
Contacts
Mikko SeppänenChief Physician, Principal Investigator for the Study, DocentHUS Children and Adolescents, Pediatric Research Center (PRC)
Tel:+358 50 427 9606mikko.seppanen@hus.fiImages
![Mikko Seppänen](/data/images/public/23980819/70129471/6d6cc4d1-d861-4835-ae53-4aa018d27ddd-w_240.jpg)
About HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats almost 700,000 patients every year. Our nearly 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
Alternative languages
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
HUS-sammanslutningens styrelse sammanträder den 10 februari 20257.2.2025 09:23:12 EET | Pressmeddelande
HUS-sammanslutningens styrelse sammanträder måndagen den 10 februari 2025 bland annat för att godkänna HUS verkställande direktörs mål och arbetets fokusområden för 2025. Föredragningslistan för mötet finns här. Sammanslutningens styrelse leder HUS verksamhet, förvaltning och ekonomi. Sammanslutningens styrelse har 17 ledamöter och av dem är två företrädare för Helsingfors universitet. Sammanslutningens styrelse sammanträder cirka en gång per månad.
HUSin yhtymähallitus kokoontuu 10.2.20257.2.2025 09:23:12 EET | Tiedote
HUSin yhtymähallitus kokoontuu maanantaina 10.2.2025 muun muassa hyväksymään HUSin toimitusjohtajan tavoitteet ja työn painopisteet vuodelle 2025. Kokouksen esityslistan pääset lukemaan täältä. Yhtymähallitus johtaa HUSin toimintaa, hallintoa ja taloutta. Yhtymähallituksessa on 17 jäsentä, joista kaksi on Helsingin yliopiston edustajia. Yhtymähallitus kokoontuu noin kerran kuukaudessa. HUSin mediapalvelu palvelee mediaa ma–to klo 10–16, pe klo 10–15 numerossa 050 427 2875 tai sähköpostitse viestinta@hus.fi.
HUS sparade över 7 miljoner euro genom att minska användningen av hyrd arbetskraft6.2.2025 12:06:48 EET | Pressmeddelande
Viktiga metoder för att minska användningen av hyrd arbetskraft vid HUS 2024 var en mer omfattande delning av bästa praxis samt nytt stödmaterial för ekonomiuppföljningen.
HUS säästi yli 7 miljoonaa euroa vähentämällä vuokratyövoiman käyttöä6.2.2025 12:06:48 EET | Tiedote
Keskeisiä keinoja HUSin vuokratyövoiman käytön vähentämisessä vuonna 2024 olivat parhaiden käytäntöjen laajempi jakaminen sekä talousseurannan uudet tukimateriaalit.
Operationsverksamheten vid HUS ökade 20244.2.2025 09:50:26 EET | Pressmeddelande
Vid HUS gjordes i fjol totalt 91 572 operationer. Antalet operationsåtgärder ökade fyra procent jämfört med året innan. I synnerhet antalet elektiva, det vill säga planerade operationer ökade.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom